Treace Medical Concepts, Inc.
NASDAQ:TMCIMedical - Devices
+$0.08 today
- Market cap
- $296.98M
- Beta
- 1.41
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.95
Volume 0.18M
Average 0.73M
TMCI Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Treace Medical Concepts, Inc.NASDAQ: TMCI
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $17.96M (cash outflow) rose 12.8% year over year, behind the +15.2% change in trailing-twelve-month net income. Sequentially, it rose 91.2% from the prior quarter. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Net income amounted to 27.7% of revenue in FY2025, up 1.1 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$51.38M (-12.9%) for the fiscal year ending Dec 2026, a slowdown from the +5.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$17.96M+91.2% QoQ
- Last fiscal yearDec 2025
- -$59M+5.8% YoY
- LTMMar 2026
- -$61.04M+15.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.8% | +12.1% | -0.7 pp |
| 1 year | +5.8% | -12.9% | -18.8 pp |
| 3-year CAGR | +11.3% | -10.3% | -21.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (59M) USD
- Year-over-year change
- -5.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (59M) | -5.8% |
| FY2024 | 2024-12-31 | (55.74M) | -12.6% |
| FY2023 | 2023-12-31 | (49.53M) | -15.7% |
| FY2022 | 2022-12-31 | (42.82M) | -108.3% |
| FY2021 | 2021-12-31 | (20.55M) | — |
Net Income vs competitors
How TMCI compares with its peers on the latest reported figures
- TMCI's LTM Mar 2026 net income of $61.04M is the 2nd largest of the 8 companies compared; the peer median is $39.68M.
- Its year-over-year change of +15.2% is the 5th highest of 8, against a peer median of +35.0%.
- Net income amounts to 29.4% of revenue for TMCI, versus a peer median of 16.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.21M | +158.9% | -26.7% | 90.7% | |
| LTM Mar 2026 | $61.04M | +15.2% | +11.3% | 29.4% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $60.37M | +35.0% | +12.9% | 63.5% |
| LTM Mar 2026 | $46.64M | +75.7% | -16.4% | 36.6% | |
| LTM Mar 2026 | $43.42M | -22.7% | -11.5% | 14.4% | |
| LTM Mar 2026 | $39.68M | -2.5% | — | 16.3% | |
| LTM Mar 2026 | $33.69M | +201.9% | — | 5.8% | |
| LTM Mar 2026 | $4.27M | -93.1% | — | 0.8% | |
| Peer median (excluding TMCI) | $39.68M | +35.0% | -14.0% | 16.3% | |
Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.55M) | (42.82M) | (49.53M) | (55.74M) | (59M) |
| Depreciation & Amortization | 685K | 2.13M | 5.35M | 8.42M | 10.5M |
| Deferred Income Tax | 419K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.41M | 8.11M | 17.35M | 30.6M | 33.82M |
| Change in Working Capital | (1.33M) | (5.81M) | (9.74M) | (25.43M) | (8.58M) |
| Accounts Receivables | (4.23M) | (11.04M) | (9.3M) | (5.69M) | (2.09M) |
| Inventory | (3.09M) | (8.77M) | (9.85M) | (10.01M) | 3.22M |
| Accounts Payables | 1.79M | 4.61M | 3.17M | (1.31M) | (3.8M) |
| Other Working Capital | 4.19M | 9.39M | 6.24M | (8.42M) | (5.92M) |
| Other Non-Cash Items | 176K | 7.73M | 1.99M | 4.99M | 7.29M |
| Operating Cash Flow | (17.19M) | (30.65M) | (34.58M) | (37.17M) | (15.97M) |
| Capital Expenditures | (2.71M) | (14.84M) | (11.46M) | (11.59M) | (13.52M) |
| Acquisitions (Net) | 0 | 61.68M | (20M) | 0 | 0 |
| Purchases of Investments | 0 | (63.41M) | (169.87M) | (71.58M) | (40.57M) |
| Sales of Investments | 0 | 1.73M | 120.02M | 118.55M | 67.34M |
| Other Investing Activities | 0 | (61.68M) | 0 | 0 | 0 |
| Investing Cash Flow | (2.71M) | (76.52M) | (81.3M) | 35.38M | 13.25M |
| Debt Repayment | (1.79M) | 19.61M | 0 | 0 | 2.43M |
| Common Stock Issued | 109.44M | 2.19M | 109.4M | 428K | 546K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (989K) | (13K) | (268K) | (902K) |
| Financing Cash Flow | 107.65M | 20.81M | 109.38M | 160K | 2.08M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 87.75M | (86.36M) | (6.49M) | (1.63M) | (642K) |
| Free Cash Flow | (19.9M) | (45.49M) | (46.03M) | (48.76M) | (29.49M) |
Treace Medical Concepts, Inc.
NASDAQ:TMCI
Intrinsic Alpha fair value
Locked
Current Price
$4.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.